0 O F Ε S R P N C Р TERNA MEDICINE THE LANDMARK 20th FDITION

20th Edition ERNAL MEDICINE

> JAMESON FAUCI KASPER HAUSER LONGO LOSCALZO

VOLUME 1

Mc Graw Hill

20th Edition

19pters 231-477

JAMESON FAUCI KASPER HAUSER LONGO LOSCALZO

20th Edition

Chapters 1-230

MASTER MODERN MEDICINE

Harrison's Landmark 20th Edition is your guide to mastering the complexity of modern medicine with:

- The latest clinical trials results & treatment recommendations
- New & updated content in general & specialty medicine
- Cutting-edge pathophysiology
- Support for differential diagnosis with details on causes of symptoms



NTERNAL MEDICINE S NOTINE VOLUME 1


JAMESON FAUCI KASPER HAUSER LONGO LOSCALZO

20th Edition



It's a Harrison's year!

- Publication Date: INSERT
- Available in stores: INSERT
- Available on AccessMedicine: from 2018
- List Price: INSERT
- Markets:
 - Internal Medicine
 - General and Family Medicine
 - Senior-level Medical Students
 - ► Trainees in Medicine





In an increasingly complex world of medicine, Harrison's 20th edition is more relevant than ever, with a refreshed, user-friendly design and cutting-edge new content that reflects the latest foundational, bioscientific, and clinical insights across the full spectrum of medicine.

20th Edition RN MEDICINE JAMESON VOLUME 2 FAUCI KASPER HAUSER LONGO I OSCALZO VOLUME 1



Essential for both practice and education, new features include:

- Thoroughly revised content covering new breakthroughs in clinical medicine
- State-of-the-art coverage of disease mechanisms: Harrison's focuses on pathophysiology with rigor, and with the goal of linking disease mechanisms to treatments.
- New sections covering a wide range of new and emerging areas of vital interest to all healthcare professionals.
- Frontiers in Medicine, addresses cutting-edge topics in research and medicine such as epigenetics, genomics and infectious disease, telomere function, and more.
- Updated clinical guidelines, expert opinions, and treatment approaches provide clinicians with most up-to date guidelines and a clear blueprint for optimizing patient outcomes.



Essential for both practice and education, new features include:

- Fully updated "Cardinal Manifestations of Disease" explains the underlying physiologic, anatomical, and biochemical changes that result in the outward expression of signs and symptoms.
- Timely new chapters offering the very latest, definitive perspectives on mustknow topics in medical education and practice.
- Optimized coverage of "The Profession of Medicine" re-organized to focus on the bedrock principles of what it means to practice medicine in the 21st century.
- Hundreds of new images and visuals, providing clinical guidance at-a-glance.



The numbers behind it

- 68 years in publication
- 6 Editors
- 700+ contributors
- 2 volumes even volume split between 1) Symptoms and 2) Diseases
- 4,200 book pages
- 0 DVD with this edition! Media chapters now available online

- 1,600 illustrations
- 1,400 tables ranging from simple to very complex
- 200 decision tress/algorithms
- More than a dozen brand new chapters
- Several brand new Parts



Appendix



Competitor Titles	Author	Edition	Publisher	Pub Date	ISBN-13	ISBN-10	Price USD
Goldman-Cecil Medicine, 2-Volume Set	Goldman, Lee	25 th Edition	Elsevier LTD, Oxford	May 11, 2015	9781455750177	1455750174	\$199.99
Davidson's Principles and Practice of Medicine	Colledge, Nicki R.	22 nd Edition	Churchill Livingstone	Feb 15, 2014	9780702050350	0702030856	\$85.95
Kumar and Clark's Clinical Medicine	Parveen Kumar, Michael L Clark	9 th Edition	Elsevier LTD, Oxford	Sept 26, 2016	9780702066016	070206601X	\$90.99
Goldman's Cecil Expert Consult Single Volume	Goldman, Lee	24 th Edition	Elsevier LTD, Oxford	Aug 5, 2011	9781437716047	1437716040	\$143.93
Oxford Textbook of Medicine, 3 -Vol	Warrell, David A.	1 st Edition	Oxford University Press	July 22, 2010	9780199204854	0199204853	\$730.00
The Merck Manual of Diagnosis and Therapy	Robert S. Porter	20th Edition	Merck	Apr 17, 2018	9780911910421	0911910425	\$79.95



Brand new parts!

Covering a wide range of new and emerging areas of vital interest to all healthcare professionals. Addresses cuttingedge topics in research and medicine.

Entire new Parts! These include:

- Frontiers of Medicine;
- Medical Consultation;
- Diabetes, Obesity, and Metabolic Syndrome;
- Gender-based Healthcare; and more

PART 20 Frontiers


468 Behavioral Economics and Health Kevin G. Volpp, George Loewenstein, David A. Asch
469 Complementary, Alternative, and Integrative Health Approaches Josephine P. Briggs
470 Telomere Disease Rodrigo T. Calado, Neal S. Young
471 The Role of Epigenetics in Disease and Treatment Brian C. Capell, Shelley L. Berger
472 Mitochondrial DNA and Heritable Traits and Diseases



Brand new chapters!

Offers the very latest, definitive perspectives on must-know topics in medical education and practice. A large number of brand new chapters on critical topics in medicine, such as:

- Pharmacogenomics;
- LGBT Health;
- Promoting Good Health;
- Health Systems;
- Approach to Medical Consultation and more!



The previous chapter discussed mechanisms underlying variability in drug action, highlighting pharmacokinetic and pharmacodynamic pathways to beneficial and adverse drug events. Work in the past several decades has defined how genetic variation can play a prominent role in modulating these pathways. Initial studies described unusual drug responses due to single genetic variants in individual subjects, defining the field of pharmacogenetics. A more recent view extends this idea to multiple genetic variants across populations, and the term "pharmacogenomics" is often used. Understanding the role of genetic variation in drug response could improve the use of current drugs, avoid drug use in those at increased risk for adverse drug reactions (ADRs), guide development of new drugs, and even be used as a lens through which to understand mechanisms of diseases themselves. This chapter will outline the principles of pharmacogenomics, the evidence as currently available that genetic factors play a role in variable drug actions, and outline areas of controversy and future work.



Updated content on critical topics

Thoroughly revised content – covers new breakthroughs in clinical medicine. Chapters on from new Hepatitis and Cancer drugs to the latest in disease demographics and pathogenic mechanisms.

Deliver the latest information on disease mechanisms, diagnostic options, and the specific treatment guidance needed to provide optimal patient care. 334 Chronic Hepatitis Jules L. Dienstag

Chronic hepatitis represents a series of liver disorders of varying causes and severity in which hepatic inflammation and necrosis continue for at least 6 months. Milder forms are nonprogressive or only slowly progressive, while more severe forms may be associated with scarring and architectural reorganization, which, when advanced, lead ultimately to cirrhosis. Several categories of chronic hepatitis have been recognized. These include chronic viral hepatitis, drug-induced chronic hepatitis (Chap. 333), and autoimmune chronic hepatitis. In many cases, clinical and laboratory features are insufficient to allow assignment into one of these three categories; these "idiopathic" cases are also believed to represent autoimmune chronic hepatitis. Finally, clinical and laboratory features of chronic hepatitis are observed occasionally in patients with such hereditary/metabolic disorders as Wilson's disease (copper overload), α_1 antitrypsin deficiency (Chaps. 337 and 408), and nonalcoholic fatty liver disease (Chap. 336) and even occasionally in patients with alcoholic liver injury (Chap. 335). Although all types of chronic hepatitis share certain clinical, laboratory, and histopathologic features, chronic viral and chronic autoimmune hepatitis are sufficiently distinct to merit separate discussions. For discussion of acute hepatitis, see Chap. 332.

CLASSIFIC

Clinical and se of *chronic viral* hepatitis C; *auto* based on serole category of unk These are addre

CLASSIFIC

Grade, a histolo examination of features include limiting plate or *piecemeal necros* that links or f portal tract and of hepatocyte of histologic featur are the histolog States, and the l the presence an hepatitis can be

CLASSIFIC

The stage of chu the disease, is b



New text design

A brighter, more modern and appealing layout.


Readers can navigate through the material faster.


TREATMENT	DOSAGE	COMMENTS		
Acetaminophen	Up to 1 g tid	Prolongs half-life of warfarin. Make sure patient is not taking other treatments containing acetaminophen to avoid hepatic toxicity.		
Oral NSAIDs and COX-2 inhibitors Naproxen Salsalate Ibuprofen Celecoxib	375–500 mg bid 1500 mg bid 600–800 mg 3–4 times a day 100-200 mg qd	ulcers and bleeding, occur. Patients at high risk for gastrointestinal side effects shou also take either a proton pump inhibitor or misoprostol. ^a There is an increase in gastrointestinal side effects or bleeding when taken with acetylsalicylic acid. Can also		
Topical NSAIDs		Rub onto joint. Few systemic side effects. Skin irritation common.		
Diclofenac Na 1% gel	4 g qid (for knees, hands)			
Opiates	Various	Common side effects include dizziness, sedation, nausea or vomiting, dry mouth, constipation, urinary retention, and pruritus. Respiratory and central nervous system depression can occur.		
Capsaicin	0.025–0.075% cream 3–4 times a day	Can irritate mucous membranes.		
Intraarticular injections				
Steroids				
Hyaluronans	Varies from 3 to 5 weekly	Mild to moderate pain at injection site. Controversy exists regarding efficacy.		



Hundreds of new images and visuals

State of- the-art drawings, schematics, radiological images, clinical visuals, and microscopic depictions, which provide clinical guidance at-a-glance.







Suggested reading

Providing clinicians with most up-to-date guidelines and a clear blueprint for optimizing patient outcomes.

detection and treatment of tuberculosis after more than a half century of research, new infectious disease outbreaks (e.g., pandemic influenza, viral hemorrhagic fevers, Zika) continue to emerge, and the threat of microbial bioterrorism remains high. The subsequent chapters in Part 5 detail—on both a syndrome and a microbe-by-microbe basis—the current state of medical knowledge about infectious diseases. At their core, all of these chapters carry a similar message: Despite numerous advances in the diagnosis, treatment, and prevention of infectious diseases, much work and research are required before anyone can confidently claim we have achieved "the virtual elimination of infectious disease." In reality, this goal will never be attained, given the rapid adaptability of microbes.

FURTHER READING

PART

Infectious

Diseases

BARTLETT JG: Why infectious diseases. Clin Infect Dis 59(Suppl 2):S85, 2014.

KHABBAZ RF et al: Challenges of infectious diseases in the USA. Lancet 384:53, 2014.

MARSTON HD et al: Antimicrobial resistance. JAMA 316:1193, 2016. SCHMITT S et al: Infectious diseases specialty intervention is associated with decreased mortality and lower healthcare costs. Clin Infect Dis 58:22, 2014.

VERGHESE A et al: Inadequacies of physical examination as a cause of medical errors and adverse events: A collection of vignettes. Am J Med 128:1322, 2015.

interest in in or on r microbes on physic immune s of host–pa have docu and even everyday

The Mic organisms

plants are overall ho establish t microbes host cells a and differ rently cha and bioint type 1 di skin, gast developm to directly logic state species an



Thank

YOU

20th Edition VOLUME 2 20th Edition AMESON JAMESON FAUCI KASPER HAUSER LONGO LOSCALZO Chapters 1-230

VOLUME

VOLUME 1

Mc Graw Hill

20th Edition RINCIPLES OF INTERNAL MEDICINE

JAMESON FAUCI KASPER HAUSER LONGO LOSCALZO